Physician profile
Adeel Masood
NPI 1093156028
$904.13
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $129 · 2021: $135 · 2022: $354 · 2023: $23.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $232.52 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $194.37 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $120.38 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $81.45 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $53.56 | 2019-2022 | |
| Pfizer INC. | $47.94 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.33 | 2019-2020 | |
| Shire North American Group INC | $24.87 | 2019 | |
| Eisai INC. | $21.77 | 2022 | |
| Csl Behring | $18.50 | 2019 | |
| Gilead Sciences, INC. | $18.15 | 2022 | |
| Sunovion Pharmaceuticals INC. | $17.54 | 2019 | |
| Novo Nordisk INC | $14.91 | 2021 | |
| W. L. Gore & Associates, INC. | $14.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adeel Masood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.